CN103003278A - 芳胺基嘌呤衍生物及其制备方法和在医药上的用途 - Google Patents

芳胺基嘌呤衍生物及其制备方法和在医药上的用途 Download PDF

Info

Publication number
CN103003278A
CN103003278A CN2010800670272A CN201080067027A CN103003278A CN 103003278 A CN103003278 A CN 103003278A CN 2010800670272 A CN2010800670272 A CN 2010800670272A CN 201080067027 A CN201080067027 A CN 201080067027A CN 103003278 A CN103003278 A CN 103003278A
Authority
CN
China
Prior art keywords
preparation
purine derivatives
pharmaceutical use
arylamino purine
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2010800670272A
Other languages
English (en)
Other versions
CN103003278B (zh
Inventor
杨胜勇
魏于全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
Sichuan University
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University, CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical Sichuan University
Priority to CN201080067027.2A priority Critical patent/CN103003278B/zh
Priority to CN201610205716.4A priority patent/CN105832740B/zh
Publication of CN103003278A publication Critical patent/CN103003278A/zh
Application granted granted Critical
Publication of CN103003278B publication Critical patent/CN103003278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Abstract

公开了式I所示的芳胺基嘌呤衍生物及其制备方法，其中各取代基如说明书中所定义。该化合物对表皮生长因子受体(EGFR)19外显子缺失突变或21外显子L858R点突变的非小细胞肺癌具有抑制作用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201080067027.2A 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途 Active CN103003278B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201080067027.2A CN103003278B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途
CN201610205716.4A CN105832740B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2010101844786A CN102260263A (zh) 2010-05-26 2010-05-26 一类二苯胺基嘌呤衍生物及制备方法和医药用途
CN2010101844786 2010-05-26
CN201010184478.6 2010-05-26
PCT/CN2010/002126 WO2011147066A1 (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途
CN201080067027.2A CN103003278B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610205716.4A Division CN105832740B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途

Publications (2)

Publication Number Publication Date
CN103003278A true CN103003278A (zh) 2013-03-27
CN103003278B CN103003278B (zh) 2016-03-30

Family

ID=45003189

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010101844786A Pending CN102260263A (zh) 2010-05-26 2010-05-26 一类二苯胺基嘌呤衍生物及制备方法和医药用途
CN201080067027.2A Active CN103003278B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途
CN201610205716.4A Active CN105832740B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010101844786A Pending CN102260263A (zh) 2010-05-26 2010-05-26 一类二苯胺基嘌呤衍生物及制备方法和医药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610205716.4A Active CN105832740B (zh) 2010-05-26 2010-12-23 芳胺基嘌呤衍生物及其制备方法和在医药上的用途

Country Status (7)

Country Link
US (1) US9096601B2 (zh)
EP (1) EP2578584B1 (zh)
JP (1) JP5662564B2 (zh)
KR (1) KR101839915B1 (zh)
CN (3) CN102260263A (zh)
ES (1) ES2814257T3 (zh)
WO (1) WO2011147066A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
EP2809659A1 (en) 2012-02-03 2014-12-10 Basf Se Fungicidal pyrimidine compounds
JP2015511940A (ja) 2012-02-03 2015-04-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
US9462809B2 (en) 2012-03-13 2016-10-11 Basf Se Fungicidal pyrimidine compounds
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
AU2018325442B2 (en) * 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
CN107892691B (zh) * 2017-12-19 2020-04-28 西安交通大学 2,8,9-三取代-9h-嘌呤类化合物及其盐和应用
CN110078732A (zh) * 2018-01-26 2019-08-02 沈阳药科大学 嘌呤类化合物及其用途
US11266624B2 (en) * 2018-04-03 2022-03-08 Texas Tech University System CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
US20220387435A1 (en) * 2019-11-09 2022-12-08 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of multi-target protein kinase inhibitor
US20230144619A1 (en) * 2020-01-22 2023-05-11 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Salt of arylaminopurine derivative, preparation method therefor and use thereof
EP4272741A1 (en) 2020-12-31 2023-11-08 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Pharmaceutical composition of multi-target protein kinase inhibitors, and use thereof
WO2022179592A1 (zh) * 2021-02-25 2022-09-01 石药集团中奇制药技术（石家庄）有限公司 一种急性髓系白血病的联合治疗药物
CN113582995B (zh) * 2021-08-17 2022-08-16 西安交通大学 9-位含有丙烯酰氨基片段的-9h-嘌呤类化合物及其盐和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097135A2 (en) * 2004-04-05 2005-10-20 Novartis Ag Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
EP2172461A1 (en) * 2007-07-06 2010-04-07 Astellas Pharma Inc. Di(arylamino)aryl compound
CA2740471A1 (en) * 2008-10-14 2010-04-22 Daiichi Sankyo Company, Limited Morpholinopurine derivatives
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
CN101142215A (zh) * 2005-01-13 2008-03-12 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
WO2005097135A2 (en) * 2004-04-05 2005-10-20 Novartis Ag Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP2172461A1 (en) * 2007-07-06 2010-04-07 Astellas Pharma Inc. Di(arylamino)aryl compound
CA2740471A1 (en) * 2008-10-14 2010-04-22 Daiichi Sankyo Company, Limited Morpholinopurine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAS ET AL.: "Dithiocarbamate and CuO promoted one-pot synthesis of 2-(N-subsituted)-aminobenzimidazoles and related heterocycles", 《TETRAHEDRON LETTERS》 *
SABAT M ET AL.: "The development of novel C-2,C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
EP2578584B1 (en) 2020-08-12
KR101839915B1 (ko) 2018-05-04
EP2578584A1 (en) 2013-04-10
US9096601B2 (en) 2015-08-04
EP2578584A4 (en) 2013-10-30
CN105832740B (zh) 2019-02-12
CN103003278B (zh) 2016-03-30
JP2013528164A (ja) 2013-07-08
KR20130109984A (ko) 2013-10-08
JP5662564B2 (ja) 2015-02-04
US20130203986A1 (en) 2013-08-08
CN105832740A (zh) 2016-08-10
WO2011147066A1 (zh) 2011-12-01
ES2814257T3 (es) 2021-03-26
CN102260263A (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
CN103003278A (zh) 芳胺基嘌呤衍生物及其制备方法和在医药上的用途
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
WO2016109559A3 (en) Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
WO2014033447A3 (en) Diaryl urea derivatives as p38 map kinase inhibitors
MX2007007272A (es) 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
NZ609448A (en) Tricyclic pi3k inhibitor compounds and methods of use
MY148583A (en) Pyridine [3,4-b] pyrazinones
MX344025B (es) Inhibidores de proteínas quinasas.
WO2015061247A3 (en) Heteroaryl compounds as btk inhibitors and uses thereof
FR2959510B1 (fr) Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2005082340A3 (en) Modulation of inflammatory and metastatic processes
PH12015500376B1 (en) Novel bicyclic pyridinones
MX2013012387A (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinocetan (folfiri).
WO2011101069A3 (en) 1, 8 -naphthyridines as kinase inhibitors
HK1200447A1 (zh) -吡咯並 吡啶衍生物及它們作為激酶抑制劑的用途
NZ616764A (en) Mannose derivatives as antagonists of bacterial adhesion
PL2658844T3 (pl) Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
MX361157B (es) Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.
WO2012109605A3 (en) Forms of rifaximin and uses thereof
NO20092902L (no) 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]kinolinforbindelser nyttige som PDE5-inhibitorer
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220113

Address after: 050035 226 the Yellow River Avenue, Shijiazhuang high tech Industrial Development Zone, Hebei

Patentee after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Patentee after: CSPC PHARMACEUTICAL GROUP OUYI PHARMA Co.,Ltd.

Patentee after: SICHUAN University

Address before: No. 226, the Yellow River Avenue, Shijiazhuang hi tech Industrial Development Zone, Hebei

Patentee before: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Patentee before: Sichuan University

TR01 Transfer of patent right